Cholesterol byproduct blocks heart health benefits of estrogen

September 16, 2007

New findings by UT Southwestern Medical Center researchers show that a byproduct of cholesterol metabolism interferes with the beneficial effects estrogen has on the cardiovascular system, providing a better understanding of the interplay between cholesterol and estrogen in heart disease.

The results of the study, available online and in the October issue of the journal Nature Medicine, also may explain why hormone replacement therapy fails to protect some postmenopausal women from heart disease, said Dr. David Mangelsdorf, chairman of pharmacology and senior author of the paper.

The researchers found that in rodents, a molecule called 27-hydroxycholesterol, or 27HC, binds to the same receptors in the blood vessels of the heart to which estrogen binds.

The normal result of this estrogen binding is that blood vessel walls remain elastic and dilated, and damage to the vasculature is repaired, among other heart-protective effects. Other research has shown that postmenopausal women – who no longer produce estrogen – lose this protective action and become more susceptible to heart disease.

Based on their animal studies and other experiments, the UT Southwestern researchers determined that when estrogen levels dropped relative to the amount of 27HC circulating in the blood, 27HC reacted and bound to the estrogen receptors in the cardiovascular system and blocked their protective function, primarily by inhibiting the production of nitric oxide. Nitric oxide mediates smooth muscle relaxation in blood vessels, aids cell growth and repair, and prevents thrombosis. Reduced levels of nitric oxide in blood vessels has been linked with high cholesterol and diabetes.

In animals fed a high-fat, high-cholesterol diet, both cholesterol and 27HC levels were elevated.

“We found that 27HC can effectively inhibit estrogen function in vascular tissue by binding to estrogen receptors,” said Dr. Mangelsdorf, a Howard Hughes Medical Institute investigator at UT Southwestern. “This study not only illustrates the damaging effects high cholesterol has on the heart but also supports the notion that the relative levels of 27HC and estrogen in the vasculature are contributing factors to the risk for cardiovascular disease.”

In normal premenopausal women, the amount of 27HC generated from cholesterol is relatively low compared to the level of estrogen circulating in the blood, leading to enhanced cardiovascular protection. In contrast, when the level of 27HC is higher relative to estrogen, such as during the postmenopausal period or as a consequence of high cholesterol, the researchers speculate that 27HC out-competes estrogen to bind with estrogen receptors, blocking the function of the receptors and resulting in a loss of protection.

“This model may help explain why women are better protected than men from cardiovascular disease until they reach menopause,” said Dr. Mangelsdorf.

The findings also may help explain why a large clinical trial that evaluated certain hormone replacement therapies (HRT) in postmenopausal women – a component of the 15-year Women’s Health Initiative – had to be halted in 2002 when the hormones appeared to increase a woman’s risk of heart disease.

“In the Women’s Health Initiative research program, the women who began taking HRT were an average of 13 years postmenopause,” Dr. Manglesdorf said. “By the time they started taking this estrogen again, the damage caused by 27HC binding to the estrogen receptors in the cardiovascular system may already have occurred. Once you lose estrogen’s protection for such an extended period of time, you can’t get it back.”

The researchers also found that 27HC works predominantly on estrogen receptors in the cardiovascular system. When it binds to estrogen receptors in other tissues, such as reproductive tissues, it has no effect on their reproduction-related functions. This property of 27HC makes it a “selective estrogen receptor modulator,” or SERM, the first such naturally occurring molecule known to exhibit such selectivity.

“This molecule is remarkable in its selectivity for the vasculature,” Dr. Mangelsdorf said. “These findings also validate the estrogen receptor as a possible drug target for manufactured SERMs.”

Source: UT Southwestern Medical Center

Explore further: High cholesterol fuels the growth and spread of breast cancer

Related Stories

High cholesterol fuels the growth and spread of breast cancer

November 28, 2013
A byproduct of cholesterol functions like the hormone estrogen to fuel the growth and spread of the most common types of breast cancers, researchers at the Duke Cancer Institute report.

New driver of breast cancer discovered

November 7, 2013
A team of researchers at UT Southwestern has found that as cholesterol is metabolized, a potent stimulant of breast cancer is created – one that fuels estrogen-receptor positive breast cancers, and that may also defeat ...

New driver of atherosclerosis offers potential as therapeutic target

June 19, 2014
A new driver of atherosclerosis has been identified by researchers at UT Southwestern Medical Center. This molecule, known as 27HC (27-hydroxycholesterol), has been found to exacerbate the development of the condition, and ...

Recommended for you

Basic research in fruit flies leads to potential drug for diseases afflicting millions

July 13, 2018
River blindness and elephantiasis are debilitating diseases caused by parasitic worms that infect as many as 150 million people worldwide. They are among the "neglected tropical diseases" for which better treatments are desperately ...

Light based cochlear implant restores hearing in gerbils

July 12, 2018
A team of researchers with members from a variety of institutions across Germany has developed a new type of cochlear implant—one based on light. In their paper published in the journal Science Translational Medicine, the ...

Researchers discover gene that controls bone-to-fat ratio in bone marrow

July 12, 2018
In an unexpected discovery, UCLA researchers have found that a gene previously known to control human metabolism also controls the equilibrium of bone and fat in bone marrow as well as how an adult stem cell expresses its ...

Intensive care patients' muscles unable to use fats for energy

July 12, 2018
The muscles of people in intensive care are less able to use fats for energy, contributing to extensive loss of muscle mass, finds a new study co-led by UCL, King's College London and Guy's and St Thomas' NHS Foundation Trust.

Blood biomarker can help predict disease progression in patients with COPD

July 12, 2018
Some patients with COPD demonstrate signs of accelerated aging. In a new study published in the journal CHEST researchers report that measuring blood telomeres, a marker of aging of cells, can be used to predict future risk ...

Rogue molecules provoke out-of-control scar tissue, strangle organs

July 12, 2018
Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases—kidney, liver and lung fibrosis—the scar tissue goes rogue and strangles vital organs. These diseases ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.